Therapeutics

in silico

in silico

Virtual screening to identify target compounds through both ligand-based and structure-based approaches

in vitro

in vitro

Leveraging extensive clinical metadata to screen and evaluate compounds and discovering new agents effective against microbial infections.

in vivo

in vivo

In vivo testing on selected preclinical models to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of repurposed compounds in a biological system. "From Molecule to Model – Validating with Life”

Rational, mechanism-driven discovery of novel therapeutics for infectious and inflammatory disease, directed at the proteins and pathways that sustain disease persistence and drive loss of therapeutic response. Generative models trained on comprehensive, unbiased chemical, structural and biological datasets design and optimise candidate molecules, which advance through in vitro target engagement and in vivo efficacy and pharmacokinetic validation.

OUR PIPELINE

Product Portfolio

Four preclinical programs across antimicrobials, oncology and dermatology.

4 Programs
3 Therapeutic areas
Program
Discovery
Preclinical
Phase I
Phase II
Phase III
Antimicrobials 2 programs
SC004 + SCAB1 Combination
Preclinical
SC006 Antimicrobial
Preclinical
Oncology 1 program
SCON1 Oncology
Preclinical
Dermatology 1 program
SCDERM1 Dermatology
Preclinical